相似文献
1
Deuterated 1,3 Dihydro‑2‑indole-2-one Derivatives for Treatment of Depression or Anxiety.
ACS Med Chem Lett. 2025 May 28;16(6):965-966. doi: 10.1021/acsmedchemlett.5c00284. eCollection 2025 Jun 12.
2
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
3
Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.
Cochrane Database Syst Rev. 2018 Sep 28;9(9):CD003481. doi: 10.1002/14651858.CD003481.pub7.
4
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.
Cochrane Database Syst Rev. 2024 Sep 12;9(9):CD015383. doi: 10.1002/14651858.CD015383.pub2.
5
Psychological interventions for treatment of inflammatory bowel disease.
Cochrane Database Syst Rev. 2025 Apr 17;4(4):CD006913. doi: 10.1002/14651858.CD006913.pub3.
6
Psychological interventions for coronary heart disease.
Cochrane Database Syst Rev. 2017 Apr 28;4(4):CD002902. doi: 10.1002/14651858.CD002902.pub4.
7
Antidepressants for depression in adults with HIV infection.
Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD008525. doi: 10.1002/14651858.CD008525.pub3.
8
Exercise interventions and patient beliefs for people with hip, knee or hip and knee osteoarthritis: a mixed methods review.
Cochrane Database Syst Rev. 2018 Apr 17;4(4):CD010842. doi: 10.1002/14651858.CD010842.pub2.
9
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
10
Brexanolone, zuranolone and related neurosteroid GABA receptor positive allosteric modulators for postnatal depression.
Cochrane Database Syst Rev. 2025 Jun 26;6(6):CD014624. doi: 10.1002/14651858.CD014624.pub2.
本文引用的文献
1
Evidence for the contribution of vasopressin V1 receptors in the pathophysiology of depression.
Biochem Pharmacol. 2025 Jan;231:116672. doi: 10.1016/j.bcp.2024.116672. Epub 2024 Nov 26.
2
Structural Basis for Antagonist Binding to Vasopressin V1b Receptor Revealed by the Molecular Dynamics Simulations.
Biopolymers. 2025 Jan;116(1):e23627. doi: 10.1002/bip.23627. Epub 2024 Sep 17.
3
Arginine vasopressin in mood disorders: A potential biomarker of disease pathology and a target for pharmacologic intervention.
Psychiatry Clin Neurosci. 2024 Sep;78(9):495-506. doi: 10.1111/pcn.13703. Epub 2024 Jun 25.
4
Targeting the Arginine Vasopressin V Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders.
Neuropsychiatr Dis Treat. 2023 Apr 12;19:811-828. doi: 10.2147/NDT.S402831. eCollection 2023.
5
Vasopressin V1B Receptor Antagonists as Potential Antidepressants.
Int J Neuropsychopharmacol. 2021 Jul 14;24(6):450-463. doi: 10.1093/ijnp/pyab013.
6
Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
Drug Discov Today. 2010 Oct;15(19-20):826-41. doi: 10.1016/j.drudis.2010.08.001. Epub 2010 Aug 11.
Zotero 插件